Global Duchenne Muscular Dystrophy Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028
Executive Summary
According to GRD Survey data, the global Duchenne Muscular Dystrophy market is estimated at 1360 million US$ in 2021 and is expected to reach 21400 million US$ by the end of 2028, growing at a CAGR of 48.3% in the forecast period between 2022 and 2028.
This report studies the Duchenne Muscular Dystrophy market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Duchenne Muscular Dystrophy in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)
Market Snapshot, By Product Type
Exondys 51
Emflaza
Translarna
Market Snapshot, By Application
Hospitals
Clinics
Home Care
Main Market Players Analyzed in this report, including:
Sarepta Therapeutics
Santhera Pharmaceuticals
PTC Therapeutics
Pfizer
Italfarmaco
Bristol-Myers Squibb
The study objectives of this report are:
To study and analyze the global Duchenne Muscular Dystrophy market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Duchenne Muscular Dystrophy market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Duchenne Muscular Dystrophy manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Duchenne Muscular Dystrophy market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Duchenne Muscular Dystrophy submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027
This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries
Table of Content
Table of Contents
1 Market Definition & Scope
1.1 Definition & Scope
1.2 Duchenne Muscular Dystrophy Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Duchenne Muscular Dystrophy Market Performance and Outlook
2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Duchenne Muscular Dystrophy
3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Duchenne Muscular Dystrophy Sales Channel and Distributors Analysis
3.3.1 Duchenne Muscular Dystrophy Sales Channel
3.3.2 Duchenne Muscular Dystrophy Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Hospitals
3.4.2 Major Buyers in Clinics
3.5 Duchenne Muscular Dystrophy Manufacturing Cost Structure Analysis
4 Market Segment: by Type
4.1 Duchenne Muscular Dystrophy Type Introduction
4.1.1 Exondys 51
4.1.2 Emflaza
4.1.3 Translarna
4.2 Global Duchenne Muscular Dystrophy Sales by Type 2016-2021
4.3 Global Duchenne Muscular Dystrophy Revenue by Type 2016-2021
4.4 Global Duchenne Muscular Dystrophy Price by Type 2016-2021
5 Market Segment: by Application
5.1 Duchenne Muscular Dystrophy Type Introduction
5.1.1 Hospitals
5.1.2 Clinics
5.1.3 Home Care
5.2 Global Duchenne Muscular Dystrophy Sales by Application 2016-2021
5.3 Global Duchenne Muscular Dystrophy Revenue by Application 2016-2021
5.4 Global Duchenne Muscular Dystrophy Price by Application 2016-2021
6 Marke Segment: by Region
6.1 Global Duchenne Muscular Dystrophy Market by Region
6.1.1 Global Duchenne Muscular Dystrophy Sales by Regions
6.1.2 Global Duchenne Muscular Dystrophy Revenue by Regions
6.2 North America Duchenne Muscular Dystrophy Market 2016-2021
6.3 Europe Duchenne Muscular Dystrophy Market 2016-2021
6.4 Asia Pacific Duchenne Muscular Dystrophy Market 2016-2021
6.5 South America Duchenne Muscular Dystrophy Market 2016-2021
6.6 Middle East and Africa Duchenne Muscular Dystrophy Market 2016-2021
7 North America
7.1 North America Duchenne Muscular Dystrophy Market by Country 2016-2021
7.1.1 North America Duchenne Muscular Dystrophy Sales by Country
7.1.2 North America Duchenne Muscular Dystrophy Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico
8 Europe
8.1 Europe Duchenne Muscular Dystrophy Market by Country 2016-2021
8.1.1 Europe Duchenne Muscular Dystrophy Sales by Country
8.1.2 Europe Duchenne Muscular Dystrophy Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain
9 Asia Pacific
9.1 Asia Pacific Duchenne Muscular Dystrophy Market by Country 2016-2021
9.1.1 Asia Pacific Duchenne Muscular Dystrophy Sales by Country
9.1.2 Asia Pacific Duchenne Muscular Dystrophy Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia
10 South America
10.1 South America Duchenne Muscular Dystrophy Market by Country 2016-2021
10.1.1 South America Duchenne Muscular Dystrophy Sales by Country
10.1.2 South America Duchenne Muscular Dystrophy Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Duchenne Muscular Dystrophy Market by Country 2016-2021
11.1.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country
11.1.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa
12 Key Participants Company Information
12.1 Sarepta Therapeutics
12.1.1 Sarepta Therapeutics Company Information
12.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio, Specification and Application
12.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 Sarepta Therapeutics Key Development
12.2 Santhera Pharmaceuticals
12.2.1 Santhera Pharmaceuticals Company Information
12.2.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio, Specification and Application
12.2.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Santhera Pharmaceuticals Key Development
12.3 PTC Therapeutics
12.3.1 PTC Therapeutics Company Information
12.3.2 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio, Specification and Application
12.3.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 PTC Therapeutics Key Development
12.4 Pfizer
12.4.1 Pfizer Company Information
12.4.2 Pfizer Duchenne Muscular Dystrophy Product Portfolio, Specification and Application
12.4.3 Pfizer Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Pfizer Key Development
12.5 Italfarmaco
12.5.1 Italfarmaco Company Information
12.5.2 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio, Specification and Application
12.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Italfarmaco Key Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Company Information
12.6.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio, Specification and Application
12.6.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 Bristol-Myers Squibb Key Development
13 Global Duchenne Muscular Dystrophy Market Forecast by Region by Type and by Application
13.1 Global Duchenne Muscular Dystrophy Sales, Revenue Forecast 2022-2027
13.2 Global Duchenne Muscular Dystrophy Forecast by Regions
13.2.1 Global Duchenne Muscular Dystrophy Sales Forecast by Region 2022-2027
13.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Region 2022-2027
13.3 Global Duchenne Muscular Dystrophy Forecast by Type
13.3.1 Global Duchenne Muscular Dystrophy Sales Forecast by Type 2022-2027
13.3.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Type 2022-2027
13.3.3 Global Duchenne Muscular Dystrophy Price Forecast by Type 2022-2027
13.4 Global Duchenne Muscular Dystrophy Forecast by Application
13.4.1 Global Duchenne Muscular Dystrophy Sales Forecast by Application 2022-2027
13.4.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Application 2022-2027
13.4.3 Global Duchenne Muscular Dystrophy Price Forecast by Application 2022-2027
14 Analyst Views and Conclusions
15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices